MEDICAL ETHICS:@0.099415:0.051227:0.278670:0.051227:0.278670:0.029663:0.099415:0.029663:0.020855:0.012164:0.016884:0.005129:0.018450:0.016793:0.010484:0.006286:0.012164:0.009667:0.015500:0.005129:0.018450:0.011301
38:@0.040417:0.051430:0.060750:0.051430:0.060750:0.028888:0.040417:0.028888:0.010167:0.010167
HAnDBook oF MEDICAL ETHICS:@0.099415:0.959549:0.357162:0.959549:0.357162:0.943867:0.099415:0.943867:0.011272:0.012213:0.012213:0.012279:0.009473:0.014342:0.014342:0.009754:0.004572:0.014342:0.008005:0.004572:0.015167:0.008846:0.012279:0.003730:0.013418:0.012213:0.007625:0.004572:0.008846:0.007031:0.011272:0.003730:0.013418:0.008219
antigenicity of the biosimilar can be tested :@0.098830:0.534487:0.481168:0.534487:0.481168:0.516844:0.098830:0.516844:0.012384:0.011010:0.005979:0.003416:0.012180:0.011772:0.011010:0.003416:0.011716:0.003416:0.005979:0.009655:0.005867:0.011846:0.005533:0.005867:0.005997:0.011010:0.011753:0.005867:0.012366:0.003416:0.011846:0.006907:0.003416:0.017119:0.003416:0.003416:0.012384:0.005273:0.005867:0.011716:0.012384:0.011010:0.005867:0.012366:0.011772:0.005867:0.005979:0.011753:0.006907:0.005997:0.011753:0.012719:0.005143
in preclinical and clinical research, but when :@0.098830:0.550827:0.481149:0.550827:0.481149:0.533183:0.098830:0.533183:0.003342:0.010955:0.003936:0.012292:0.005217:0.011697:0.011642:0.003342:0.003342:0.010955:0.003342:0.011642:0.012310:0.003342:0.003936:0.012310:0.010769:0.012162:0.003751:0.011456:0.003156:0.003156:0.010769:0.003156:0.011456:0.012124:0.003156:0.003751:0.005032:0.011512:0.006647:0.011512:0.012124:0.005032:0.011456:0.010769:0.004586:0.003936:0.012292:0.010918:0.005923:0.003936:0.015058:0.010955:0.011697:0.011326:0.005143
rare may only manifest years after being :@0.098830:0.567166:0.481149:0.567166:0.481149:0.549523:0.098830:0.549523:0.005793:0.012886:0.005793:0.012273:0.006387:0.017620:0.012904:0.010175:0.006387:0.012366:0.011530:0.003936:0.010175:0.006387:0.017620:0.012904:0.011530:0.003936:0.006034:0.012273:0.007427:0.006499:0.006387:0.010175:0.012273:0.012904:0.005793:0.007427:0.006387:0.012886:0.006034:0.006499:0.012273:0.005793:0.006387:0.012886:0.012273:0.003936:0.011530:0.012496:0.005143
used in uniquely susceptible individuals. This :@0.098830:0.583506:0.481130:0.583506:0.481130:0.565863:0.098830:0.565863:0.010918:0.006833:0.011697:0.012347:0.005682:0.003342:0.010955:0.005682:0.010918:0.010955:0.003342:0.012292:0.010918:0.011697:0.003342:0.009581:0.005682:0.006833:0.010918:0.006833:0.011642:0.011697:0.012292:0.005923:0.003342:0.012292:0.003342:0.011697:0.005682:0.003342:0.010955:0.012347:0.003342:0.009915:0.003342:0.012347:0.010918:0.012310:0.003342:0.006833:0.004772:0.005682:0.007538:0.010955:0.003342:0.007204:0.005143
places an additional pharmacovigilance :@0.098830:0.599845:0.481205:0.599845:0.481205:0.582202:0.098830:0.582202:0.012774:0.003825:0.012793:0.012124:0.012180:0.007316:0.006276:0.012793:0.011437:0.006276:0.012793:0.012830:0.012830:0.003825:0.006406:0.003825:0.012273:0.011437:0.012793:0.003825:0.006276:0.012774:0.011437:0.012793:0.005700:0.017528:0.012793:0.012124:0.012273:0.010398:0.003825:0.012607:0.003825:0.003825:0.012793:0.011437:0.012124:0.012069:0.005143
requirement on the manufacturer, which :@0.098830:0.616185:0.481093:0.616185:0.481093:0.598542:0.098830:0.598542:0.005756:0.012236:0.012830:0.011456:0.003881:0.005756:0.012236:0.017583:0.012236:0.011493:0.006461:0.006331:0.012329:0.011493:0.006331:0.006461:0.011493:0.012236:0.006331:0.017583:0.012849:0.011493:0.011456:0.005997:0.012849:0.012180:0.006461:0.011456:0.005756:0.012236:0.005756:0.005310:0.006331:0.015597:0.011493:0.003881:0.012180:0.011326:0.005143
again increases costs. :@0.098830:0.632525:0.293248:0.632525:0.293248:0.614881:0.098830:0.614881:0.012310:0.012124:0.012310:0.003342:0.010955:0.004772:0.003342:0.010955:0.011642:0.005217:0.011697:0.012310:0.006833:0.011697:0.006833:0.004772:0.011642:0.011790:0.006833:0.005923:0.006833:0.005143:0.005143
The originator companies have now :@0.116377:0.648864:0.481223:0.648864:0.481223:0.631221:0.116377:0.631221:0.008894:0.012310:0.013053:0.007148:0.013146:0.006573:0.004698:0.013480:0.004698:0.012310:0.013666:0.007278:0.013146:0.006573:0.007148:0.012997:0.013146:0.018400:0.013647:0.013666:0.012310:0.004698:0.013053:0.008188:0.007148:0.012310:0.013666:0.011270:0.013053:0.007148:0.012310:0.013146:0.015429:0.005143
started to “clone” their own products by :@0.098830:0.665204:0.481001:0.665204:0.481001:0.647561:0.098830:0.647561:0.007427:0.006517:0.012904:0.005812:0.006517:0.012292:0.012941:0.006387:0.006517:0.012384:0.006387:0.009544:0.012236:0.003936:0.012384:0.011549:0.012292:0.009209:0.006387:0.006517:0.011549:0.012292:0.003936:0.005812:0.006387:0.012384:0.015652:0.011549:0.006387:0.012886:0.005812:0.012384:0.012941:0.011512:0.012236:0.006517:0.007427:0.006387:0.012886:0.009952:0.005143
selling them at a cheaper price (e.g., 20% :@0.098830:0.681544:0.481130:0.681544:0.481130:0.663900:0.098830:0.663900:0.007390:0.012254:0.003899:0.003899:0.003899:0.011512:0.012681:0.004512:0.006480:0.011512:0.012254:0.017602:0.004512:0.012867:0.006480:0.004512:0.012867:0.004512:0.012199:0.011512:0.012254:0.012867:0.012849:0.012254:0.005774:0.004512:0.012849:0.005774:0.003899:0.012199:0.012254:0.004512:0.007037:0.012254:0.005329:0.012681:0.005329:0.005329:0.004512:0.010472:0.010472:0.014390:0.005143
less) and under new branding. This is to :@0.098830:0.697883:0.481019:0.697883:0.481019:0.680240:0.098830:0.680240:0.004252:0.012607:0.007743:0.007743:0.007390:0.006721:0.013220:0.011864:0.013257:0.006721:0.011827:0.011864:0.013257:0.012607:0.006127:0.006721:0.011864:0.012607:0.015968:0.006703:0.013201:0.006127:0.013220:0.011864:0.013257:0.004252:0.011864:0.013034:0.005682:0.006721:0.008448:0.011864:0.004270:0.007743:0.006721:0.004252:0.007743:0.006721:0.006833:0.012162:0.005143
stave off the threat of biosimilars entering :@0.098830:0.714223:0.481205:0.714223:0.481205:0.696580:0.098830:0.696580:0.007390:0.006480:0.012867:0.010472:0.012254:0.005236:0.012347:0.006016:0.006016:0.005236:0.006480:0.011512:0.012254:0.005236:0.006480:0.011512:0.005774:0.012254:0.012867:0.006480:0.005236:0.012347:0.006016:0.005236:0.012849:0.003899:0.012347:0.007390:0.003899:0.017602:0.003899:0.003899:0.012867:0.005774:0.007390:0.005236:0.012254:0.011512:0.006480:0.012254:0.005774:0.003899:0.011512:0.012496:0.005143
the market at more or less the same price :@0.098830:0.730562:0.481149:0.730562:0.481149:0.712919:0.098830:0.712919:0.006480:0.011512:0.012254:0.004865:0.017602:0.012867:0.005774:0.009506:0.012254:0.006480:0.004865:0.012867:0.006480:0.004865:0.017602:0.012347:0.005774:0.012254:0.004865:0.012347:0.005774:0.004865:0.003899:0.012254:0.007390:0.007390:0.004865:0.006480:0.011512:0.012254:0.004865:0.007390:0.012867:0.017602:0.012254:0.004865:0.012849:0.005774:0.003899:0.012199:0.012069:0.005143
reduction. The issue of access is, there-:@0.098830:0.746902:0.476173:0.746902:0.476173:0.729259:0.098830:0.729259:0.006201:0.012681:0.013331:0.011902:0.012626:0.006907:0.004326:0.012774:0.011939:0.005756:0.006777:0.008522:0.011939:0.012681:0.006777:0.004326:0.007817:0.007817:0.011902:0.012681:0.006777:0.012774:0.006443:0.006777:0.013294:0.012626:0.012626:0.012681:0.007817:0.007817:0.006777:0.004326:0.007817:0.005756:0.006777:0.006907:0.011939:0.012681:0.006201:0.012681:0.006164
fore, only partially addressed in that :@0.098830:0.763242:0.481186:0.763242:0.481186:0.745599:0.098830:0.745599:0.007204:0.013536:0.006963:0.013443:0.006517:0.007538:0.013536:0.012700:0.005087:0.011326:0.007538:0.014037:0.014055:0.006963:0.007668:0.005087:0.014055:0.005087:0.005087:0.011326:0.007538:0.014055:0.014093:0.014093:0.006963:0.013443:0.008578:0.008578:0.013443:0.014093:0.007538:0.005087:0.012700:0.007538:0.007668:0.012700:0.014055:0.006294:0.005143
when treatment costs reach millions of :@0.098830:0.779581:0.481279:0.779581:0.481279:0.761938:0.098830:0.761938:0.016154:0.012050:0.012793:0.012050:0.006888:0.007018:0.006313:0.012793:0.013406:0.007018:0.018140:0.012793:0.012050:0.007018:0.006888:0.012737:0.012886:0.007928:0.007018:0.007928:0.006888:0.006313:0.012793:0.013406:0.012737:0.012050:0.006888:0.018140:0.004438:0.004438:0.004438:0.004438:0.012886:0.012050:0.007928:0.006888:0.012886:0.005830:0.005143
rands to prolong the life of one patient, :@0.098830:0.795921:0.481038:0.795921:0.481038:0.778278:0.098830:0.778278:0.006016:0.013108:0.011753:0.013146:0.007631:0.006591:0.006721:0.012589:0.006591:0.013090:0.006016:0.012589:0.004141:0.012589:0.011753:0.012923:0.006591:0.006721:0.011753:0.012496:0.006591:0.004141:0.004141:0.006257:0.012496:0.006591:0.012589:0.006257:0.006591:0.012589:0.011753:0.012496:0.006591:0.013090:0.013108:0.006721:0.004141:0.012496:0.011753:0.006721:0.005143:0.005143
the societal impact may be of such a :@0.098830:0.812261:0.481223:0.812261:0.481223:0.794617:0.098830:0.794617:0.007223:0.012254:0.012997:0.007093:0.008132:0.013090:0.012941:0.004642:0.012997:0.007223:0.013610:0.004642:0.007093:0.004642:0.018344:0.013591:0.013610:0.012941:0.007223:0.007093:0.018344:0.013610:0.010880:0.007093:0.013591:0.012997:0.007093:0.013090:0.006758:0.007093:0.008132:0.012217:0.012941:0.012254:0.007093:0.012681:0.005143
nature that it remains inaccessible even :@0.098830:0.828600:0.481260:0.828600:0.481260:0.810957:0.098830:0.810957:0.011697:0.013053:0.006666:0.011660:0.005960:0.012440:0.006536:0.006666:0.011697:0.013053:0.006666:0.006536:0.004085:0.006666:0.006536:0.005960:0.012440:0.017787:0.013053:0.004085:0.011697:0.007575:0.006536:0.004085:0.011697:0.013053:0.012384:0.012384:0.012440:0.007575:0.007575:0.004085:0.013034:0.004085:0.012440:0.006536:0.012440:0.010658:0.012440:0.011326:0.005143
at the reduced price. It may be neces-:@0.098830:0.844940:0.475969:0.844940:0.475969:0.827297:0.098830:0.827297:0.013220:0.006814:0.006703:0.006814:0.011846:0.012589:0.006703:0.006109:0.012589:0.013257:0.011809:0.012533:0.012589:0.013257:0.006703:0.013201:0.006109:0.004252:0.012533:0.012589:0.005663:0.006703:0.004735:0.006814:0.006703:0.017936:0.013220:0.010491:0.006703:0.013201:0.012589:0.006703:0.011846:0.012589:0.012533:0.012589:0.007743:0.006164
sary to re-assess the regulatory framework :@0.098830:0.861279:0.481168:0.861279:0.481168:0.843636:0.098830:0.843636:0.007390:0.012867:0.005774:0.010138:0.004326:0.006480:0.012347:0.004326:0.005774:0.012254:0.006350:0.012867:0.007390:0.007390:0.012254:0.007390:0.007390:0.004326:0.006480:0.011512:0.012254:0.004326:0.005774:0.012254:0.012681:0.011475:0.003899:0.012867:0.006480:0.012347:0.005774:0.010138:0.004326:0.006016:0.005774:0.012867:0.017602:0.012254:0.015615:0.012347:0.005774:0.009321:0.005143
for these entities within poorer countries :@0.098830:0.877619:0.481223:0.877619:0.481223:0.859976:0.098830:0.859976:0.006257:0.012589:0.006016:0.006591:0.006721:0.011753:0.012496:0.007631:0.012496:0.006591:0.012496:0.011753:0.006721:0.004141:0.006721:0.004141:0.012496:0.007631:0.006591:0.015856:0.004141:0.006721:0.011753:0.004141:0.011753:0.006591:0.013090:0.012589:0.012589:0.006016:0.012496:0.006016:0.006591:0.012440:0.012589:0.011716:0.011753:0.006721:0.006016:0.004141:0.012496:0.007204:0.005143
such as South Africa in order to address :@0.098830:0.893959:0.481186:0.893959:0.481186:0.876316:0.098830:0.876316:0.007631:0.011716:0.012440:0.011753:0.006591:0.013108:0.007631:0.006591:0.009674:0.012589:0.011716:0.006721:0.011753:0.006591:0.014167:0.006257:0.006016:0.004141:0.012440:0.013108:0.006591:0.004141:0.011753:0.006591:0.012589:0.006016:0.013146:0.012496:0.006016:0.006591:0.006721:0.012589:0.006591:0.013108:0.013146:0.013146:0.006016:0.012496:0.007631:0.007204:0.005143
the specific issue of access to expensive :@0.098830:0.910298:0.480926:0.910298:0.480926:0.892655:0.098830:0.892655:0.006554:0.011586:0.012329:0.006424:0.007464:0.012923:0.012329:0.012273:0.003973:0.004651:0.004651:0.012273:0.006424:0.003973:0.007464:0.007464:0.011549:0.012329:0.006424:0.012422:0.006090:0.006424:0.012941:0.012273:0.012273:0.012329:0.007464:0.007464:0.006424:0.006554:0.012422:0.006424:0.012329:0.009172:0.012923:0.012329:0.011586:0.007464:0.003973:0.010546:0.012069:0.005143
biological medicines. It is even difficult for :@0.098830:0.926638:0.481205:0.926638:0.481205:0.908995:0.098830:0.908995:0.012849:0.003899:0.012347:0.003899:0.012347:0.012681:0.003899:0.012199:0.012867:0.003899:0.004735:0.017602:0.012254:0.012904:0.003899:0.012199:0.003899:0.011512:0.012254:0.007390:0.005329:0.004735:0.004382:0.006480:0.004735:0.003899:0.007390:0.004735:0.012254:0.010472:0.012254:0.011512:0.004735:0.012904:0.003899:0.006016:0.004614:0.004614:0.012199:0.011475:0.003899:0.006480:0.004735:0.006016:0.012347:0.005589:0.005143
more robust economies such as the :@0.522814:0.533880:0.905040:0.533880:0.905040:0.516237:0.522814:0.516237:0.019050:0.013795:0.007223:0.013703:0.007798:0.007223:0.013795:0.014297:0.012923:0.008838:0.007928:0.007798:0.013703:0.013647:0.013795:0.012960:0.013795:0.019050:0.005347:0.013703:0.008838:0.007798:0.008838:0.012923:0.013647:0.012960:0.007798:0.014315:0.008838:0.007798:0.007928:0.012960:0.012069:0.005143
United States of America to cope with the :@0.522814:0.550246:0.905207:0.550246:0.905207:0.532603:0.522814:0.532603:0.012347:0.011512:0.003899:0.006480:0.012254:0.012904:0.004289:0.009432:0.006480:0.012867:0.006480:0.012254:0.007390:0.004289:0.012347:0.006016:0.004289:0.013925:0.017602:0.012254:0.005774:0.003899:0.012199:0.012867:0.004289:0.006480:0.012347:0.004289:0.012199:0.012347:0.012849:0.012254:0.004289:0.015615:0.003899:0.006480:0.011512:0.004289:0.006480:0.011512:0.012069:0.005143
high price of biosimilars. Is the significant :@0.522814:0.566611:0.905040:0.566611:0.905040:0.548968:0.522814:0.548968:0.011586:0.003992:0.012756:0.011586:0.006443:0.012923:0.005849:0.003973:0.012273:0.012329:0.006443:0.012422:0.006090:0.006443:0.012923:0.003973:0.012422:0.007464:0.003992:0.017676:0.003992:0.003973:0.012941:0.005849:0.007464:0.005403:0.006443:0.004456:0.007483:0.006443:0.006554:0.011586:0.012329:0.006424:0.007483:0.003973:0.012756:0.011586:0.003992:0.004651:0.004651:0.012273:0.012941:0.011586:0.006294:0.005143
rise in individual bankruptcies of late a :@0.522814:0.582977:0.904910:0.582977:0.904910:0.565333:0.522814:0.565333:0.006294:0.004419:0.007910:0.012774:0.006870:0.004419:0.012032:0.006870:0.004419:0.012032:0.013424:0.004419:0.010992:0.004419:0.013424:0.011994:0.013387:0.004419:0.006870:0.013368:0.013387:0.012032:0.010026:0.006294:0.011994:0.013368:0.007000:0.012719:0.004419:0.012774:0.007910:0.006870:0.012867:0.006536:0.006870:0.004419:0.013387:0.007000:0.012774:0.006870:0.012681:0.005143
direct result of patients trying to pay for :@0.522814:0.599342:0.905263:0.599342:0.905263:0.581699:0.522814:0.581699:0.013164:0.004159:0.006016:0.012514:0.012459:0.006740:0.006610:0.006034:0.012514:0.007650:0.011735:0.004159:0.006740:0.006610:0.012607:0.006276:0.006610:0.013108:0.013127:0.006740:0.004159:0.012514:0.011772:0.006740:0.007650:0.006610:0.006740:0.006034:0.010398:0.004159:0.011772:0.012941:0.006610:0.006740:0.012589:0.006610:0.013108:0.013127:0.010398:0.006610:0.006276:0.012589:0.005589:0.005143
these medicines?:@0.522814:0.615707:0.682920:0.615707:0.682920:0.598064:0.522814:0.598064:0.006480:0.011512:0.012254:0.007390:0.012254:0.005329:0.017602:0.012254:0.012904:0.003899:0.012199:0.003899:0.011512:0.012254:0.007390:0.010973
There has even been some suggestion :@0.540360:0.632073:0.905040:0.632073:0.905040:0.614430:0.540360:0.614430:0.008188:0.011605:0.012347:0.005867:0.012347:0.006461:0.011605:0.012960:0.007483:0.006461:0.012347:0.010565:0.012347:0.011605:0.006461:0.012941:0.012347:0.012347:0.011605:0.006461:0.007483:0.012440:0.017695:0.012347:0.006461:0.007483:0.011567:0.012774:0.012774:0.012347:0.007483:0.006573:0.003992:0.012440:0.011326:0.005143
of relooking the patent process, i.e., :@0.522814:0.648438:0.905058:0.648438:0.905058:0.630795:0.522814:0.630795:0.013498:0.007167:0.007501:0.006926:0.013406:0.005050:0.013498:0.013498:0.010658:0.005050:0.012663:0.013833:0.007501:0.007631:0.012663:0.013406:0.007501:0.014000:0.014018:0.007631:0.013406:0.012663:0.007631:0.007501:0.014000:0.006926:0.013498:0.013350:0.013406:0.008541:0.008541:0.006480:0.007501:0.005050:0.006480:0.013406:0.006480:0.005143:0.005143
prolongation to allow longer periods over :@0.522814:0.664804:0.905114:0.664804:0.905114:0.647161:0.522814:0.647161:0.012681:0.005589:0.012162:0.003732:0.012162:0.011326:0.012496:0.012681:0.006294:0.003732:0.012162:0.011326:0.006183:0.006294:0.012162:0.006183:0.012700:0.003732:0.003732:0.012162:0.015448:0.006183:0.003732:0.012162:0.011326:0.012496:0.012069:0.005589:0.006183:0.012681:0.012069:0.005589:0.003732:0.012162:0.012719:0.007223:0.006183:0.012162:0.010305:0.012069:0.005589:0.005143
which to recover development costs. :@0.522814:0.681169:0.905188:0.681169:0.905188:0.663526:0.522814:0.663526:0.016543:0.012422:0.004827:0.013127:0.012440:0.007278:0.007408:0.013257:0.007278:0.006684:0.013183:0.013127:0.013257:0.011400:0.013183:0.006684:0.007278:0.013833:0.013183:0.011400:0.013183:0.004827:0.013257:0.013777:0.018530:0.013183:0.012440:0.007390:0.007278:0.013127:0.013257:0.008318:0.007408:0.008318:0.005143:0.005143
other specific access programmes are :@0.522814:0.697535:0.905114:0.697535:0.905114:0.679892:0.522814:0.679892:0.016803:0.006944:0.011976:0.012719:0.006239:0.006833:0.007873:0.013331:0.012719:0.012663:0.004382:0.006480:0.004382:0.012663:0.006833:0.013350:0.012663:0.012663:0.012719:0.007873:0.007873:0.006833:0.013331:0.006239:0.012811:0.013146:0.006239:0.013350:0.018085:0.018066:0.012719:0.007873:0.006833:0.013350:0.006239:0.012069:0.005143
under consideration globally to ensure :@0.522814:0.713900:0.905151:0.713900:0.905151:0.696257:0.522814:0.696257:0.012032:0.012069:0.013461:0.012811:0.006331:0.006907:0.012756:0.012904:0.012069:0.007947:0.004456:0.013461:0.012811:0.006331:0.013424:0.007037:0.004456:0.012904:0.012069:0.006907:0.013238:0.004456:0.012904:0.013406:0.013424:0.004456:0.004456:0.010695:0.006907:0.007037:0.012904:0.006907:0.012811:0.012069:0.007947:0.012032:0.006331:0.012069:0.005143
sustained development of these new enti-:@0.522814:0.730266:0.900008:0.730266:0.900008:0.712622:0.522814:0.712622:0.007204:0.011289:0.007204:0.006294:0.012681:0.003713:0.011326:0.012069:0.012719:0.004920:0.012719:0.012069:0.010286:0.012069:0.003713:0.012162:0.012663:0.017416:0.012069:0.011326:0.006294:0.004902:0.012162:0.005830:0.004902:0.006294:0.011326:0.012069:0.007204:0.012069:0.004920:0.011326:0.012069:0.015429:0.004920:0.012069:0.011326:0.006294:0.003713:0.006164
ties but with greater market guarantees to :@0.522814:0.746631:0.905151:0.746631:0.905151:0.728988:0.522814:0.728988:0.006294:0.003713:0.012069:0.007204:0.004772:0.012663:0.011289:0.006294:0.004772:0.015429:0.003713:0.006294:0.011326:0.004772:0.012496:0.005589:0.012050:0.012681:0.006294:0.012069:0.005589:0.004772:0.017416:0.012681:0.005589:0.009321:0.012069:0.006294:0.004753:0.012496:0.011289:0.012681:0.005589:0.012681:0.011326:0.006294:0.012069:0.012069:0.007204:0.004772:0.006294:0.012162:0.005143
reduce cost in order to enhance access. :@0.522814:0.762996:0.905244:0.762996:0.905244:0.745353:0.522814:0.745353:0.005682:0.012180:0.012830:0.011400:0.012124:0.012180:0.006276:0.012124:0.012254:0.007316:0.006406:0.006276:0.003825:0.011437:0.006276:0.012254:0.005700:0.012830:0.012180:0.005682:0.006276:0.006387:0.012273:0.006276:0.012180:0.011419:0.011437:0.012793:0.011437:0.012124:0.012180:0.006276:0.012793:0.012124:0.012124:0.012180:0.007316:0.007316:0.005143:0.005143
In some developed markets, risk-sharing :@0.522814:0.779362:0.905021:0.779362:0.905021:0.761719:0.522814:0.761719:0.004605:0.011735:0.006573:0.007613:0.012570:0.017825:0.012477:0.006573:0.013127:0.012477:0.010695:0.012477:0.004122:0.012570:0.013071:0.012477:0.013127:0.006573:0.017825:0.013090:0.005997:0.009729:0.012477:0.006703:0.007613:0.005552:0.006573:0.005997:0.004122:0.007613:0.009729:0.006573:0.007613:0.011735:0.013090:0.005997:0.004122:0.011735:0.012496:0.005143
agreements are in place whereby the :@0.522814:0.795727:0.904966:0.795727:0.904966:0.778084:0.522814:0.778084:0.013554:0.013368:0.006461:0.012941:0.012941:0.018289:0.012941:0.012199:0.007167:0.008077:0.007037:0.013554:0.006461:0.012941:0.007037:0.004586:0.012199:0.007037:0.013536:0.004586:0.013554:0.012886:0.012941:0.007037:0.016302:0.012199:0.012941:0.006461:0.012941:0.013536:0.010825:0.007037:0.007167:0.012199:0.012069:0.005143
funder of the product gets a payback if :@0.522814:0.812093:0.905263:0.812093:0.905263:0.794450:0.522814:0.794450:0.006164:0.011623:0.011660:0.013053:0.012403:0.005923:0.006499:0.012477:0.006164:0.006499:0.006629:0.011660:0.012403:0.006499:0.012997:0.005923:0.012477:0.013053:0.011623:0.012347:0.006629:0.006499:0.012830:0.012403:0.006629:0.007538:0.006499:0.013016:0.006499:0.012997:0.013016:0.010286:0.012997:0.013016:0.012347:0.009655:0.006499:0.004048:0.005830:0.005143
the product fails for a particular patient. :@0.522814:0.828458:0.905040:0.828458:0.905040:0.810815:0.522814:0.810815:0.006573:0.011605:0.012347:0.006461:0.012941:0.005867:0.012440:0.012997:0.011567:0.012292:0.006573:0.006461:0.006109:0.012960:0.004011:0.003992:0.007483:0.006461:0.006109:0.012440:0.005867:0.006443:0.012960:0.006461:0.012941:0.012960:0.005867:0.006573:0.004011:0.012292:0.011567:0.004011:0.012960:0.005867:0.006461:0.012941:0.012960:0.006573:0.004011:0.012347:0.011605:0.006573:0.005143:0.005143
These schemes are well described and, as :@0.522814:0.844824:0.905133:0.844824:0.905133:0.827181:0.522814:0.827181:0.007910:0.011326:0.012069:0.007204:0.012069:0.004920:0.007204:0.012013:0.011326:0.012069:0.017416:0.012069:0.007204:0.004920:0.012681:0.005589:0.012069:0.004920:0.015429:0.012069:0.003713:0.003713:0.004920:0.012719:0.012069:0.007204:0.012013:0.005589:0.003713:0.012663:0.012069:0.012719:0.004920:0.012681:0.011326:0.012719:0.005143:0.004920:0.012681:0.007204:0.005143
they also allow data gathering and insight :@0.522814:0.861189:0.905133:0.861189:0.905133:0.843546:0.522814:0.843546:0.006294:0.011326:0.012069:0.009952:0.004809:0.012681:0.003713:0.007204:0.012162:0.004809:0.012681:0.003713:0.003713:0.012162:0.015429:0.004827:0.012719:0.012681:0.006294:0.012681:0.004827:0.012496:0.012681:0.006294:0.011326:0.012069:0.005589:0.003713:0.011326:0.012477:0.004827:0.012681:0.011326:0.012719:0.004827:0.003713:0.011326:0.007204:0.003713:0.012496:0.011326:0.006294:0.005143
into the response to the new biological :@0.522814:0.877555:0.905058:0.877555:0.905058:0.859911:0.522814:0.859911:0.004270:0.011864:0.006833:0.012700:0.006721:0.006833:0.011864:0.012607:0.006721:0.006127:0.012607:0.007761:0.013201:0.012700:0.011864:0.007743:0.012607:0.006721:0.006833:0.012700:0.006721:0.006833:0.011864:0.012607:0.006721:0.011864:0.012607:0.015968:0.006721:0.013201:0.004270:0.012700:0.004270:0.012700:0.013034:0.004252:0.012551:0.013220:0.003713:0.005143
when used freely in the medical commu-:@0.522814:0.893920:0.900027:0.893920:0.900027:0.876277:0.522814:0.876277:0.015485:0.011382:0.012124:0.011382:0.006220:0.011345:0.007260:0.012124:0.012774:0.006220:0.005886:0.005644:0.012124:0.012124:0.003769:0.010008:0.006220:0.003769:0.011382:0.006220:0.006350:0.011382:0.012124:0.006220:0.017472:0.012124:0.012774:0.003769:0.012069:0.012737:0.003769:0.006220:0.012069:0.012217:0.017472:0.017472:0.011345:0.006164
nity,  this  may  lead  to  future  price :@0.522814:0.910285:0.905021:0.910285:0.905021:0.892642:0.522814:0.892642:0.013591:0.005979:0.008560:0.012217:0.007408:0.005143:0.003286:0.008560:0.013591:0.005979:0.009469:0.005143:0.003286:0.019681:0.014947:0.012217:0.005143:0.003286:0.005979:0.014334:0.014947:0.014984:0.005143:0.003286:0.008560:0.014427:0.005143:0.003286:0.008095:0.013554:0.008560:0.013554:0.007854:0.014334:0.005143:0.003286:0.014928:0.007854:0.005979:0.014278:0.012069:0.005143
reductions  based on volumes  and :@0.522814:0.926651:0.905003:0.926651:0.905003:0.909008:0.522814:0.909008:0.007798:0.014278:0.014928:0.013498:0.014223:0.008504:0.005923:0.014371:0.013536:0.009414:0.005143:0.003231:0.014872:0.014891:0.009414:0.014278:0.014928:0.008392:0.014371:0.013536:0.008392:0.012496:0.014371:0.005923:0.013498:0.019626:0.014278:0.009414:0.005143:0.003231:0.014891:0.013536:0.012719:0.005143
Figure 2. Schematic diagram of the production of a recombinant protein medicine:@0.099415:0.107837:0.845386:0.107837:0.845386:0.090069:0.099415:0.090069:0.010460:0.005653:0.012069:0.012027:0.007674:0.010893:0.004167:0.011450:0.005364:0.004167:0.011285:0.009304:0.012089:0.010893:0.017742:0.010728:0.007571:0.005653:0.009304:0.004167:0.012296:0.005653:0.010893:0.012069:0.007613:0.010893:0.017742:0.004167:0.011904:0.007035:0.004167:0.007571:0.012089:0.010893:0.004167:0.012337:0.007674:0.011966:0.012296:0.012027:0.009634:0.007571:0.005653:0.011904:0.012089:0.004167:0.011904:0.007035:0.004167:0.010893:0.004167:0.007674:0.010893:0.009077:0.011904:0.017742:0.012337:0.005653:0.012089:0.010893:0.011966:0.007571:0.004167:0.012337:0.007674:0.011904:0.007468:0.010893:0.005653:0.012089:0.004167:0.017742:0.010893:0.012296:0.005653:0.009304:0.005653:0.012089:0.010893
Protein Production, Purification and Validation:@0.315425:0.338683:0.684378:0.338683:0.684378:0.320239:0.315425:0.320239:0.009358:0.005347:0.010695:0.005013:0.010695:0.004011:0.010026:0.004679:0.009358:0.005347:0.010695:0.011029:0.010026:0.010695:0.005013:0.004011:0.010695:0.010026:0.004679:0.004679:0.009358:0.010026:0.005347:0.004011:0.004345:0.004328:0.010695:0.011029:0.005013:0.004011:0.010695:0.010026:0.004679:0.011029:0.010026:0.011029:0.004679:0.011697:0.011029:0.004011:0.004011:0.011029:0.011029:0.005013:0.004011:0.010695:0.010026
Cloning and Protein Expression:@0.375635:0.137386:0.624288:0.137386:0.624288:0.118942:0.375635:0.118942:0.013034:0.004011:0.010695:0.010026:0.004011:0.010026:0.011029:0.004679:0.011029:0.010026:0.011029:0.004679:0.009358:0.005347:0.010695:0.005013:0.010695:0.004011:0.010026:0.004679:0.008689:0.009358:0.011029:0.005347:0.010695:0.007353:0.007353:0.004011:0.010695:0.010026